. Author manuscript; available in PMC: 2022 Oct 1.

Published in final edited form as: Gynecol Oncol. 2021 Jul 24;163(1):36–40. doi: 10.1016/j.ygyno.2021.07.030

Table 4.

Univariate analysis of factors associated with new onset venous thromboembolism during NACT (N=233)

	Patients at risk	New onset VTE	OR (95% CI)	p value
All	233	27
Age(years)
<70	126(54.1)	19(70.4)	0.45(0.19–1.09)	0.99
≥70	107(59.9)	8(29.6)	0.45(0.19–1.09)	0.99
Histology
Serous	196(84.1)	22(81.5)	0.89(0.29–2.3)	0.78
Non-Serous	37(15.9)	5(18.5)	0.89(0.29–2.3)	0.78
FIGO Stage
III	71(30.6)	3(11.1)	3.9(1.2–13.6)	0.03
IV	161(69.4)	24(88.9)	3.9(1.2–13.6)	0.03
Germline mutation
No mutation	144(78.7)	17(77.3)	1.1(0.38–3.19)	0.78
Positive for BRCA 1 or 2	33(21.1)	5(22.7)	1.1(0.38–3.19)	0.78
Khorana Score
<2	103(44.2)	11(40.7)	1.17(0.5–2.7)	0.84
≥2	130(55.8)	16(59.3)	1.17(0.5–2.7)	0.84

Data are expressed as n (%) unless otherwise specified

NACT, neo-adjuvant chemotherapy; VTE, venous thromboembolism; OR, Odds ratio; FIGO, The International Federation of Gynecology and Obstetrics; BRCA, Breast Cancer gene